Trial Profile
A Phase 1 Study Of Pf-05212384 (Also Known As Pki-587) Administered As An Intravenous Infusion To Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary)
- Indications Breast cancer; Colorectal cancer; Endometrial cancer; Glioblastoma; Ovarian cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; First in man
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Sep 2012 Planned end date changed from 1 Aug 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov record.
- 28 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.